XOMA Corporation (XOMA)
Q4 2011 Earnings Call
March 14, 2012; 04:30 pm ET
John Varian - Chief Executive Officer
Dr. Paul Rubin - Vice President & Chief Medical Officer
Fred Kurland - Vice President & Chief Financial Officer
Carol DeGuzman - Senior Director of Investor Relations
Matt Kaplan - Ladenburg Thalmann
Jason Kantor - RBC Capital Markets
Good day ladies and gentlemen and welcome to the XOMA, fourth quarter 2011 financial results conference call. At this time all participants are in a listen-only mode. Later we will conduct a question-and-answer session with instructions following at that time. (Operator Instructions).
I’ll now turn the call over to Carol DeGuzman, Senior Director of Investor Relations. Please begin.
Thank you operator. Good afternoon everyone. A short while ago we issued a news release, which included our financial results for the period ended December 31, 2011 and a general business update. Our Annual Report and Form 10-K is being filed with the Securities and Exchange Commission this afternoon and each of these documents will be available on our website at xoma.com. Today’s webcast also can be accessed via our website and will be available for replay until the close of business on June 10, 2012.
Leading today’s call is John Varian, XOMA’s Chief Executive Officer, who is joined by Dr. Paul Rubin, our Vice President and Chief Medical Officer and Fred Kurland, our Vice President and Chief Financial Officer.
We wish to remind our listeners that certain statements that will be made today concerning the timing of initiation of clinical trials, availability of clinical trial results, continued sales of approved products, regulatory approval of unapproved product candidates and anticipated levels of cash utilization or that otherwise relate to future periods are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts